CORREA APPLAUDS TRUMP’S EXECUTIVE ORDER ON PSYCHEDELIC THERAPY RESEARCH

SANTA ANA, CA - Today, U.S. Representative Lou Correa (CA-46) celebrated President Donald Trump's executive order to increase research into psychedelic-assisted therapy, which has been a top priority of the Congressman.

"President Trump and I agree on this one. This is good for our veterans. Psychedelics promise to cure PTSD, mental health, alcoholism, drug addiction, Alzheimer's and other ailments," said Rep. Lou Correa. "Is it the magic cure? That's what it looks like. Let's find out. First, we need to declassify from schedule one so that more medical studies are performed."

President Trump's executive order increase research into psychedelic therapies, by specifically:

• Directing the FDA to issue new guidance to researchers on how to design clinical trials for these types of drugs.

• Committing $50 million in federal funding for ibogaine research.

• Directing the Attorney General to reschedule psychedelics that have completed FDA phase 3 trials.

• Directing HHS and FDA to collaborate with the VA to increase clinical trials and data sharing on psychedelic therapies.

• Directing FDA and DEA to add ibogaine as a therapy under the Right to Try Act-which allows terminally ill patients to participate in clinical trials for treatments still under FDA review.

Rep. Correa also co-founded the Congressional Psychedelics Advancing Therapies (PATH) Caucus with Representative General Jack Bergman to address ways to alleviate the national mental health crisis through psychedelic science and research. Together, Representatives Correa and Bergman have led efforts in Congress to promote psychedelic treatments for veterans suffering from PTSD, by advocating for more research funding, making it easier for terminally ill patients to try psychedelic therapies, and eventually including approved psychedelic therapies into veterans' VA care options

###